Literature DB >> 15820455

Surgical versus chemical (botulinum toxin) sphincterotomy for chronic anal fissure: long-term results of a prospective randomized clinical and manometric study.

Antonio Arroyo1, Francisco Pérez, Pilar Serrano, Fernando Candela, Javier Lacueva, Rafael Calpena.   

Abstract

BACKGROUND: The aim of this prospective randomized trial was to compare the effectiveness and morbidity of surgical versus chemical sphincterotomy in the treatment of chronic anal fissure after a 3-year follow-up.
METHODS: Eighty patients with chronic anal fissure were treated by whether open lateral internal sphincterotomy (group 1) or chemical sphincterotomy with 25 U botulinum toxin injected into the internal sphincter (group 2). Clinical and manometric results were analyzed.
RESULTS: Overall healing was 92.5% in the open sphincterotomy group and 45% in the toxin botulinum group (P<.001). There is a group of patients with clinical (duration of disease >12 months and presence of a sentinel pile before treatment) and manometric factors (persistently elevated mean resting pressure, % of time presence of slow waves, and number of patients or the time presence ultra slow waves after treatment) associated with a higher recurrence of anal fissure. The final percentage of incontinence was 5% in the open sphincterotomy group and 0% in the botulinum toxin group (P>.05).
CONCLUSION: We recommend surgical sphincterotomy as the first therapeutic approach in patients with clinical and manometric factors of recurrence. We prefer the use of botulinum toxin in patients older than 50 years or with risk factors for incontinence, despite the higher rate of recurrence, since it avoids the greater risk of incontinence in the surgical group.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15820455     DOI: 10.1016/j.amjsurg.2004.06.045

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  34 in total

1.  Anal fissure.

Authors:  Karen N Zaghiyan; Phillip Fleshner
Journal:  Clin Colon Rectal Surg       Date:  2011-03

2.  Botulinum toxin injection versus lateral internal sphincterotomy for the treatment of chronic anal fissure: randomized prospective controlled trial.

Authors:  Neda Valizadeh; Niloufar Yahyapour Jalaly; Mohsen Hassanzadeh; Fereshteh Kamani; Zohreh Dadvar; Shapour Azizi; Babak Salehimarzijarani
Journal:  Langenbecks Arch Surg       Date:  2012-03-20       Impact factor: 3.445

3.  Botulinum toxin injection versus lateral internal sphincterotomy in the treatment of chronic anal fissure: a randomized controlled trial.

Authors:  Maged Nasr; Hussin Ezzat; Magdy Elsebae
Journal:  World J Surg       Date:  2010-11       Impact factor: 3.352

Review 4.  Controversies in the treatment of common anal problems.

Authors:  Ismail Sagap; Feza-H Remzi
Journal:  World J Gastroenterol       Date:  2006-05-28       Impact factor: 5.742

Review 5.  A review of chronic anal fissure management.

Authors:  E E Collins; J N Lund
Journal:  Tech Coloproctol       Date:  2007-08-03       Impact factor: 3.781

Review 6.  Systematic review and meta-analysis of randomized controlled trials comparing botulinum toxin injection with lateral internal sphincterotomy for chronic anal fissure.

Authors:  Wan-Jin Shao; Guo-Chun Li; Zhi-Kun Zhang
Journal:  Int J Colorectal Dis       Date:  2009-03-06       Impact factor: 2.571

7.  Anal fissure.

Authors:  Jan Rakinic
Journal:  Clin Colon Rectal Surg       Date:  2007-05

Review 8.  [Fistulas and fissures. Part II: fissures].

Authors:  W Heitland
Journal:  Chirurg       Date:  2008-05       Impact factor: 0.955

Review 9.  Botulinum toxin and anal fissure: efficacy and safety systematic review.

Authors:  Eugenia Yiannakopoulou
Journal:  Int J Colorectal Dis       Date:  2011-08-06       Impact factor: 2.571

10.  Medical and surgical treatment of chronic anal fissure: a prospective study.

Authors:  Pierpaolo Sileri; Alessandra Mele; Vito M Stolfi; Michele Grande; Giuseppe Sica; Paolo Gentileschi; Sara Di Carlo; Achille L Gaspari
Journal:  J Gastrointest Surg       Date:  2007-08-31       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.